A Phase 2 interventional study of Oral BGE-102 and Oral Placebo Matching BGE-102 in Diabetic Macular Edema (DME), sponsored by BioAge Labs, Inc.. Recruiting at 16 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by BioAge Labs, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing bevacizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Bevacizumab · Diabetic Retinopathy.
Among the 33 studies testing bevacizumab in Diabetic Retinopathy, this one has the largest planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 33rd registered.
778 studies on the registry are indexed under Diabetic Retinopathy; 142 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 33 studies testing bevacizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Isfahan University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 40+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 13 · Phase 3 10 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 80 across 481 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 30 across the 28 interventional studies. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 33 have an industry lead sponsor. The 10 most frequent:
BioAge Labs, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
BioAge Labs, Inc. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
1 of the studies testing bevacizumab in Diabetic Retinopathy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07812090BioAge Labs, Inc.A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing bevacizumab in Diabetic Retinopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.
The purpose of this study is to assess the efficacy and safety of oral once a day (QD) dosing of BGE-102 alone or BGE-102 in combination with an anti-VEGF drug compared to anti-VEGF alone in participants with CI-DME on ocular parameters over 12 weeks of treatment.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BGE-102 Capsules dosed once daily in combination with Sham intravitreal injection delivered every 4 weeks
Drug: Oral BGE-102 · Other: Sham
BGE-102 Capsules dosed once daily in combination with anti-VEGF intravitreal injection delivered every 4 weeks
Drug: Oral BGE-102 · Drug: Anti-VEGF
Placebo Capsules dosed once daily in combination with anti-VEGF intravitreal injection delivered every 4 weeks
Drug: Oral Placebo Matching BGE-102 · Drug: Anti-VEGF
Capsules
Capsules
intravitreal injection
intravitreal injection
Change in Best Corrected Visual Acuity (BCVA)
Change from Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) in the Study Eye
Time frame: Week 12
Incidence of serious adverse events (SAEs)
Time frame: Up to Week 16
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Up to Week 16
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2027, 15 months after the start.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 15 months is below that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
BioAge Labs, Inc.